D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
D2M Biotherapeutics's investors include RiverHead Capital, Delian Capital, Longpan Investment, Apricot Capital.
D2M Biotherapeutics is headquartered in Grand Cayman, Cayman Islands.
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
D2M Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"D2M Biotherapeutics — Funding & Investors." VCBacked, April 3, 2023, https://www.vcbacked.co/company/d2m-biotherapeutics. Accessed September 30, 2026.
VCBacked. (2023). D2M Biotherapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/d2m-biotherapeutics
{{cite web |title=D2M Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/d2m-biotherapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated